Celebrating 30 years of helping you give wisely
America's most independent,
assertive charity watchdog
Top Rated

National Hemophilia Foundation (National Office)

CharityWatch report issued
March 2022

Top-Rated Charity
A-
CharityWatch Grade
Our independent grade based
on a number of factors.
 
73%
Program Percentage
Amount spent on programs
relative to overhead.
 
$5
Cost to Raise $100
Amount spent to raise
$100 of contributions.

Contact Information

National Hemophilia Foundation (National Office)
7 Penn Plaza
Suite 1204
New York, NY 10001-3923

Other Names

None

Tax Status

501(c)3

Stated Mission

Dedicated to finding cures for inheritable blood disorders and to addressing and preventing the complications of these disorders through research, education and advocacy enabling people & families to thrive.

View similar charities
Charity  
Against Malaria Foundation  
ALS Association (National Office)  
American Brain Tumor Association  
American Diabetes Association  
American Heart Association  
American Kidney Fund  
American Leprosy Missions  
American Liver Foundation  
American Lung Association  
American Parkinson Disease Association  
American Sexual Health Association  
Arthritis Foundation  
Bone Health and Osteoporosis Foundation  
BrightFocus Foundation  
CDC Foundation  
Christopher & Dana Reeve Foundation  
City of Hope & Affiliates  
Crohn's & Colitis Foundation  
Cystic Fibrosis Foundation  
Defeat Diabetes Foundation  
Diabetes Action Research and Education Foundation  
Diabetes Research & Wellness Foundation  
Diabetes Research Institute Foundation  
Easterseals (National Office)  
Elizabeth Glaser Pediatric AIDS Foundation  
Epilepsy Foundation  
Foundation for AIDS Research (amfAR)  
Hearing Health Foundation  
Heart Center of America  
Huntington's Disease Society of America  
JDRF International  
Lupus Foundation of America (National Office)  
Lupus Research Alliance  
March of Dimes  
MedicAlert Foundation United States  
Mercy Ships & Affiliates  
Michael J. Fox Foundation for Parkinson's Research  
Miracle Flights  
MiracleFeet  
Movember Foundation  
Multiple Sclerosis Association of America  
Multiple Sclerosis Foundation  
Muscular Dystrophy Association  
National Caregiving Foundation  
National Emergency Medicine Association (DISSOLVED)  
National Jewish Health  
National Kidney Foundation  
National Multiple Sclerosis Society  
National Psoriasis Foundation  
Operation Smile  
Parkinson Research Foundation  
Parkinson's Foundation  
Partnership for a Healthier America  
PKD Foundation  
Project Cure  
Salk Institute for Biological Studies  
San Francisco AIDS Foundation  
Shriners Hospitals for Children  
Smile Train  
United Cerebral Palsy (National Office)  
Will Rogers Motion Picture Pioneers Foundation  
WonderWork  
Data based on Fiscal Year Ended 12/31/2020

Program Percentage: 73%

The percentage of National Hemophilia Foundation (National Office)'s cash budget it spends on programs relative to overhead (fundraising, management, and general expenses).

$19,000,000

Calculated Total Expenses

(rounded)

 

Cost to Raise $100: $5

How many dollars National Hemophilia Foundation (National Office) spends on fundraising to raise each $100 of contributions.

$16,000,000

Calculated Total Contributions

(rounded)

Government Funding

0% to 24%

Percentage of cash revenue
coming from government sources

 

Financial Documents

Entity Document Type Tax ID
National Hemophilia Foundation IRS Form 990 13-5641857
National Hemophilia Foundation Audited Financial Statements 13-5641857
Entity: National Hemophilia Foundation
Document Type: IRS Form 990
Tax ID: 13-5641857
Entity: National Hemophilia Foundation
Document Type: Audited Financial Statements
Tax ID: 13-5641857

Governance & Transparency

CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
This charity is Top-Rated
What does it mean to be Top-Rated?
 
National Hemophilia Foundation (National Office)
meets governance benchmarks.
 
National Hemophilia Foundation (National Office)
meets transparency benchmarks.
Transparency
Provides Financial Information
Audit Accessibility
Governance: Policies
Reports regularly & consistently monitoring & enforcing compliance with a written Conflict of Interest Policy
Reports required, annual disclosure by officers, directors, and key staff of interests that could give rise to conflicts
Reports having a written Whistleblower Policy
Reports having a written Document Retention and Destruction Policy
Governance: Financials
Reports providing copy of tax form to all board members prior to filing it with IRS
Reports that financial statements were audited by an independent accountant
Governance: Board of Directors
Reports at least 5 voting board members
51% or more of voting board members reported as independent
Reports documenting minutes of board and board committee meetings
Privacy Policy
Privacy Policy

  Name Title Compensation
1 Val Bias Past CEO $411,459
2 Jordana Zeger Chief Fiscal Officer $315,377
3 Leonard Valentino President/CEO $281,349
1
Name: Val Bias
Title: Past CEO
Compensation: $411,459
2
Name: Jordana Zeger
Title: Chief Fiscal Officer
Compensation: $315,377
3
Name: Leonard Valentino
Title: President/CEO
Compensation: $281,349

CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.

According to the National Hemophilia Foundation (NHF) audit of December 31, 2020 (Note 1, Nature of Organization):

"The Foundation and other independent organizations ('member chapters') actively collaborate in furthering the Foundation's mission throughout the United States. These [audited] financial statements represent only the financial position and activities of the National Hemophilia Foundation and do not include the accounts of the 'member chapters'. On June 23, 2011, five chapters merged with NHF. On February 24, 2014, a sixth chapter and on January 27, 2016 a seventh chapter was created by the Foundation; consequently, the two newly created chapters along with those of the five previously merged chapters are included in the financial statements of NHF. All other member chapters continue to operate independently of NHF and thus, are not included in the financial statements of NHF."


The seven chapters included in the 2020 audited financial statements of NHF are: (1) Central Ohio Chapter, (2) Idaho Chapter, (3) Nevada Chapter, (4) Colorado Chapter, (5) Nebraska Chapters, (6) West Virginia Chapter, and (7) Hawaii Chapter. Given that the financial activities of these seven chapters are included in NHF's audited financial statements, they also are included in CharityWatch's rating of National Hemophilia Foundation (National Office). Our rating does not include the other, independently operated chapters of NHF.

According to the National Hemophilia Foundation audit of December 31, 2020 (Note 2 re: Contributions and Grants):

"For the year ended December 31, 2020, approximately 21% of the Foundation's total support and revenue was provided by one pharmaceutical company. ... For the year ended December 31, 2019, approximately 29% of the Foundation's total support and revenue was provided by two pharmaceutical companies...

"No other grantors accounted for more than 10% of revenue for the years ended December 31, 2020 and 2019."

According to the National Hemophilia Foundation audit of December 31, 2020 (Note 7, Paycheck Protection Program Loan):

"On April 24, 2020, the Foundation received loan proceeds in the amount of $1,398,100 under the Paycheck Protection Program (the 'PPP'). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the 'CARES Act'), provides for loans to qualifying entities for amounts up to 2.5 times their 2019 average monthly payroll expenses of the qualifying entity. The PPP loan bears an interest rate of 1% per annum.

"All or a portion of the PPP loan principal and accrued interest is forgivable as long as the borrower uses the loan proceeds for eligible purposes...over a period between eight to twenty-four weeks from the date the loan proceeds are received (the 'Covered Period'). The amount of loan forgiveness could be reduced if the borrower terminates employees or reduces salaries above a certain threshold during the Covered Period and does not qualify for certain safe harbors. The unforgiven portion of the PPP Loan, if any, is payable within two years from the date of the PPP loan with a deferral of payments of principal or interest until the amount of loan forgiveness is approved by the SBA [Small Business Administration].

"As of December 31, 2020, the PPP loan is recognized as debt in the [audited] statement of financial position. The Foundation will recognize the income from forgiveness of the PPP loan when it receives the notification of forgiveness from SBA... As of April 26, 2021, the SBA has notified the Foundation that the PPP loan has been forgiven."

According to the National Hemophilia Foundation audit of December 31, 2020 (Note 14, Subsequent Events, Paycheck Protection Program Loan):

"On March 30, 2021, the Organization received loan proceeds in the amount of $1,541,013 under Second Draw provisions of the PPP [Paycheck Protection Program] as authorized by the Economic Aid to Hard-Hit Small Business, Nonprofits, and Venues Act (the 'Economic Aid Act'). The Second Draw provisions of the Economic Aid Act provides for loans to qualifying entities for amounts up to 2.5 times their 2019 or 2020 average monthly payroll expenses. The Second Draw PPP loan bears an interest rate of 1% per annum. All or a portion of the Second Draw PPP loan principal and accrued interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes...over a period between eight to twenty-four weeks from the date the Second Draw PPP loan proceeds are received (the 'Second Draw Covered Period').

"The amount of loan forgiveness could be reduced if the borrower terminates employees or reduces salaries above a certain threshold during the Second Draw Covered Period and does not qualify for certain safe harbors. The unforgiven portion of the Second Draw PPP Loan, if any, is payable over five years from the date of the PPP loan with a deferral of payments of principal or interest until the amount of loan forgiveness is approved by the SBA [Small Business Administration]. If the Foundation does not apply for forgiveness, payments begin approximately sixteen months after the loan date."


According to the National Hemophilia Foundation audit of December 31, 2020 (Note 14, Subsequent Events, COVD-19):

"The Foundation's operations and financial performance may continue to be affected by the COVID-19 virus. If the outbreak continues and conditions worsen, it may continue to adversely affect the Foundations activities, financial conditions, results of operations, and cash flows. Economic uncertainty is related to the potential reduction and/or delays in contributions related to a decrease in discretionary income from potential donors. Management is unable to estimate the financial impact, if any, related to this matter. However, the Foundation has taken steps to maintain its financial liquidity and flexibility."

According to the National Hemophilia Foundation 2020 tax filing, the Foundation reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III):

Regarding severance payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 4a):

"Val Bias received a severance package of $411,459 during 2020."

[Val Bias is reported as "Former Chief Executive Officer," with total compensation of $411,459 in 2020 (Schedule J, Part II).]


Regarding nonfixed payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 7):

"The CEO shall be eligible to receive an annual bonus of up to 10% of base salary based on performance in a contract year. The form and amount of any performance bonus shall be within the board's discretion. The bonus determination will be made pursuant to a formalized review process conducted by the board of directors."


The Foundation reports $0 under "Bonus & incentive compensation" for the President & CEO in 2020, but the Foundation reports "Bonus & incentive compensation" payments to eight other individuals. One individual received $3,000 in "Bonus & incentive compensation"; six individuals received $1,000; and one individual received $500. The reported total compensation in 2020 for the eight individuals ranged from $315,377 to $195,544 (IRS Form 990, Schedule J, Part II).


Related Articles

No related articles found